Linda Wittkop

Summary

Country: France

Publications

  1. ncbi Methodological issues in the use of composite endpoints in clinical trials: examples from the HIV field
    Linda Wittkop
    INSERM U897, Research Centre for Epidemiology and Biostatistics, Bordeaux, France
    Clin Trials 7:19-35. 2010
  2. ncbi Effect of Cytomegalovirus-Induced Immune Response, Self Antigen-Induced Immune Response, and Microbial Translocation on Chronic Immune Activation in Successfully Treated HIV Type 1-Infected Patients: The ANRS CO3 Aquitaine Cohort
    Linda Wittkop
    University Bordeaux, ISPED, Centre INSERM U897 Epidemiologie Biostatistique
    J Infect Dis 207:622-7. 2013
  3. ncbi Alternative methods to analyse the impact of HIV mutations on virological response to antiviral therapy
    Linda Wittkop
    INSERM, Unit 897, Bordeaux, France
    BMC Med Res Methodol 8:68. 2008
  4. ncbi Virological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy, ANRS CO3 Aquitaine Cohort
    Linda Wittkop
    INSERM, Unit Epidemiology and Biostatistics, Bordeaux, France
    J Antimicrob Chemother 63:1251-5. 2009
  5. ncbi Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study
    Linda Wittkop
    INSERM U897 Centre of Epidemiology and Biostatistics, ISPED Bordeaux School of Public Health, University Bordeaux Segalen, Bordeaux, France
    Lancet Infect Dis 11:363-71. 2011
  6. ncbi HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens
    Daniel Da Silva
    Laboratoire de Virologie, Bordeaux University Hospital, and EA2968, Universite Victor Segalen, Bordeaux, France
    J Antimicrob Chemother 65:1262-9. 2010
  7. ncbi Evolution of 2-long terminal repeat (2-LTR) episomal HIV-1 DNA in raltegravir-treated patients and in in vitro infected cells
    Sandrine Reigadas
    Laboratory of Virology, EA2968, University of Bordeaux 2, Bordeaux, France
    J Antimicrob Chemother 65:434-7. 2010
  8. ncbi Virological response to darunavir/ritonavir-based regimens in antiretroviral-experienced patients (PREDIZISTA study)
    Isabelle Pellegrin
    Department of Virology, Bordeaux University Hospital, Bordeaux, France
    Antivir Ther 13:271-9. 2008

Detail Information

Publications8

  1. ncbi Methodological issues in the use of composite endpoints in clinical trials: examples from the HIV field
    Linda Wittkop
    INSERM U897, Research Centre for Epidemiology and Biostatistics, Bordeaux, France
    Clin Trials 7:19-35. 2010
    ..g. rapid virological suppression) or the licensing requirements of official drug approval organizations (e.g. time to loss of virological response [TLOVR])...
  2. ncbi Effect of Cytomegalovirus-Induced Immune Response, Self Antigen-Induced Immune Response, and Microbial Translocation on Chronic Immune Activation in Successfully Treated HIV Type 1-Infected Patients: The ANRS CO3 Aquitaine Cohort
    Linda Wittkop
    University Bordeaux, ISPED, Centre INSERM U897 Epidemiologie Biostatistique
    J Infect Dis 207:622-7. 2013
    ..Therefore, the CMV-induced immune response seems to be associated with chronic immune activation in cART recipients with sustained virological suppression...
  3. ncbi Alternative methods to analyse the impact of HIV mutations on virological response to antiviral therapy
    Linda Wittkop
    INSERM, Unit 897, Bordeaux, France
    BMC Med Res Methodol 8:68. 2008
    ..Without pre-selection each mutation presented in at least one patient is considered with a different weight. We compared these two strategies with the construction of a usual genotypic score...
  4. ncbi Virological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy, ANRS CO3 Aquitaine Cohort
    Linda Wittkop
    INSERM, Unit Epidemiology and Biostatistics, Bordeaux, France
    J Antimicrob Chemother 63:1251-5. 2009
    ..We studied viro-immunological response, pharmacokinetic parameters and genotypic test results in an observational cohort of multiple ARV class-experienced patients starting a raltegravir-based regimen...
  5. ncbi Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study
    Linda Wittkop
    INSERM U897 Centre of Epidemiology and Biostatistics, ISPED Bordeaux School of Public Health, University Bordeaux Segalen, Bordeaux, France
    Lancet Infect Dis 11:363-71. 2011
    ..We investigated the effect of TDR on outcome in the first year of cART within a large European collaboration...
  6. ncbi HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens
    Daniel Da Silva
    Laboratoire de Virologie, Bordeaux University Hospital, and EA2968, Universite Victor Segalen, Bordeaux, France
    J Antimicrob Chemother 65:1262-9. 2010
    ..Our aim was to study the in vivo viral genetic pathways for resistance to raltegravir, in antiretroviral-experienced patients with virological failure (VF) on raltegravir-containing regimens...
  7. ncbi Evolution of 2-long terminal repeat (2-LTR) episomal HIV-1 DNA in raltegravir-treated patients and in in vitro infected cells
    Sandrine Reigadas
    Laboratory of Virology, EA2968, University of Bordeaux 2, Bordeaux, France
    J Antimicrob Chemother 65:434-7. 2010
    ..Our aim was to analyse the evolution of HIV-1 2-long terminal repeat (2-LTR) circular DNA in vitro and ex vivo in the presence of raltegravir...
  8. ncbi Virological response to darunavir/ritonavir-based regimens in antiretroviral-experienced patients (PREDIZISTA study)
    Isabelle Pellegrin
    Department of Virology, Bordeaux University Hospital, Bordeaux, France
    Antivir Ther 13:271-9. 2008
    ....